MIRACLE Trial Shows 40% Blinded Remission Rate in AML
Moleculin Biotech reported promising early results from its pivotal Phase 2B/3 MIRACLE trial for Annamycin in treating relapsed or refractory acute myeloid leukemia (R/R AML). The company announced on March 19, 2026, that preliminary blinded data from the trial's first 30 subjects showed a 40% composite complete remission (CRc) rate. This figure comprises a 30% complete remission (CR) rate and a 10% rate of complete remission with partial hematological recovery (CRh). These results are notable because they include a control arm and significantly outperform historical outcomes for standard cytarabine therapy alone. Approximately 35% of the subjects treated to date had failed prior venetoclax regimens, a population considered exceptionally difficult to treat.
The encouraging blinded efficacy data seen so far, particularly in a pretreated population that includes venetoclax failures, reinforces our belief that Annamycin has the potential to represent a significant advancement in AML therapy.
— Walter Klemp, Chairman and CEO.
Company Secures Cash Runway into Q3 2026
Alongside the clinical update, Moleculin disclosed its financial position for the year ended December 31, 2025. The company posted a net loss of $33.6 million, or $28.42 per share, with research and development expenses totaling $15.9 million. Moleculin ended the year with $8.9 million in cash and cash equivalents. Crucially, the company raised an additional $8.3 million in gross proceeds from financing activities in the first quarter of 2026. Management stated this provides a cash runway into the third quarter of 2026, funding operations through the anticipated mid-year data release. The stock last traded at $2.05, significantly below its 52-week high of $33.00, reflecting the high-risk, high-reward nature of its clinical development path.
Mid-2026 Data Unblinding Poses Major Catalyst
Investor focus now shifts to mid-2026, when Moleculin expects to unblind interim data from the first 45 patients enrolled in the MIRACLE trial. This event will provide the first unblinded look at Annamycin's efficacy and safety, comparing two dosage levels against a placebo control arm. A positive outcome could substantially de-risk the program and validate the drug's potential ahead of the larger Phase 3 portion of the study. Beyond AML, Moleculin is also advancing Annamycin in trials for soft tissue sarcoma lung metastases and pancreatic cancer, with a new investigator-initiated study for the latter expected to begin in 2026.
Edgen Stock·Mar 19 2026, 13:08
